Tracking joint health after starting Esperoct in hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This is a study that follows how people’s joints are doing after they start (or switch to) Esperoct, a preventive hemophilia medicine. It mainly collects real-world health information to understand joint outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your caregiver) can sign consent before any study procedures start
- You are a male age 18 or older
- You have congenital hemophilia A that is severe or moderate (FVIII activity below 5%)
- Your doctor and you have already decided to switch to Esperoct prophylaxis (prevention), independent of the study
- You switched to Esperoct within the last 2 months, or plan to switch within 1 month after joining
- You have recent baseline joint health records from routine care (within 2 months before, or up to 1 month after switching)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows male participants with hemophilia A who are already taking Esperoct® as preventive (regular) treatment. It aims to learn how well this medicine works in real-world use and monitor safety over time.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This study tests how well a new factor VIII medicine, efanesoctocog alfa, protects your joints over time. It's for people with moderate or severe hemophilia A who are just starting this treatment.
This study is looking at how well joint health can be tracked in people with severe hemophilia A who are receiving regular factor VIII treatment. It uses special markers in the blood and ultrasound to check for early joint changes.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.